Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Planchard

Showing results (61-70 of 243) with videos related to

Pageof 25
Sort By:
Cancers|June 24, 2022
Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel DiseaseRuth Gabriela Herrera-Gómez, Miruna Grecea, Claire Gallois, et al.
JTO Clinical and Research Reports|December 6, 2022
Unexpected Cardiotoxicity in Patients With <i>HER2</i>-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case ReportMariona Riudavets, Arshid Azarine, Sondes Smaali, et al.
Onkologie|June 19, 2013
Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trialsAntonin Levy, Carlos Gomez-Roca, Christophe Massard, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 2, 2019
Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessmentSami Antoun, Hugues Morel, Pierre-Jean Souquet, et al.
Tumori|May 21, 2016
Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancerFrancesco Facchinetti, Caroline Caramella, Nathalie Auger, et al.
American Journal of Clinical Oncology|August 8, 2006
Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II studyDavid Planchard, Hugues Bourgeois, Michèle Adoun, et al.
Bulletin Du Cancer|October 10, 2014
[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?]Clarisse Audigier-Valette, Nicolas Girard, Alexis B Cortot, et al.
Expert Review of Anticancer Therapy|November 22, 2014
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?Nicolas Girard, Clarisse Audigier-Valette, Alexis B Cortot, et al.
ESMO Open|June 26, 2020
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancerAntonio Passaro, Alfredo Addeo, Christophe Von Garnier, et al.
British Journal of Cancer|January 4, 2024
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancerLaura Mezquita, Marianne Oulhen, Agathe Aberlenc, et al.
Pageof 25

Showing results (61-70 of 243) with videos related to

Sort By:
Pageof 25
Cancers|June 24, 2022
Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel DiseaseRuth Gabriela Herrera-Gómez, Miruna Grecea, Claire Gallois, et al.
JTO Clinical and Research Reports|December 6, 2022
Unexpected Cardiotoxicity in Patients With <i>HER2</i>-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case ReportMariona Riudavets, Arshid Azarine, Sondes Smaali, et al.
Onkologie|June 19, 2013
Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trialsAntonin Levy, Carlos Gomez-Roca, Christophe Massard, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 2, 2019
Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessmentSami Antoun, Hugues Morel, Pierre-Jean Souquet, et al.
Tumori|May 21, 2016
Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancerFrancesco Facchinetti, Caroline Caramella, Nathalie Auger, et al.
American Journal of Clinical Oncology|August 8, 2006
Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II studyDavid Planchard, Hugues Bourgeois, Michèle Adoun, et al.
Bulletin Du Cancer|October 10, 2014
[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?]Clarisse Audigier-Valette, Nicolas Girard, Alexis B Cortot, et al.
Expert Review of Anticancer Therapy|November 22, 2014
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?Nicolas Girard, Clarisse Audigier-Valette, Alexis B Cortot, et al.
ESMO Open|June 26, 2020
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancerAntonio Passaro, Alfredo Addeo, Christophe Von Garnier, et al.
British Journal of Cancer|January 4, 2024
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancerLaura Mezquita, Marianne Oulhen, Agathe Aberlenc, et al.
Pageof 25